Molecularly targeted therapy for gastrointestinal cancer

Current Cancer Drug Targets

Volumn 5, Issue 3, 2005, Pages 171-193

  Wiedmann, Marcus W ^a   Caca, Karel ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

C kit receptor inhibitor; Epidermal growth factor receptor inhibitor; Farnesyl transferase inhibitor; Gastrointestinal cancer; Matrix metalloproteinase inhibitor; Proteasome inhibitor; Tyrosine kinase inhibitor; Vascular endothelial growth factor inhibitor

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AP 12009; AP 23573; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CANERTINIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CHETOMIN; CI 779; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPAMINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; FR 901228; GEFITINIB; GEMCITABINE; HESPERADIN; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; IMATINIB; IRINOTECAN; LAPATINIB; LY 550410; LY 580276; MAMMALIAN TARGET OF RAPAMYCIN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SB 505124; SONIC HEDGEHOG PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TANOMASTAT; THALIDOMIDE; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; VORINOSTAT; VX 608;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ANEMIA; ANGINA PECTORIS; ANGIOGENESIS; ANOREXIA; ASTHENIA; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CACHEXIA; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHOLANGITIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TARGETING; EDEMA; EPIGASTRIC PAIN; ESOPHAGUS CANCER; FATIGUE; FEVER; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GUILLAIN BARRE SYNDROME; HAND FOOT SYNDROME; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; JAUNDICE; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALAISE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUADRIPLEGIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18844429786     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053765771     Document Type: Review

References (102)

1. Schlessinger, J. Cell signalling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
2. Witte, O. N.; Dasgupta, A.; Baltimore, D. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 1980, 283, 826-831.
3. Hunter, T.; Sefton, B. M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA 1980, 77, 1311-1315.
4. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411, 355-365.
5. Cartwright, C. A.; Meisler, A. I.; Eckhart, W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA 1990, 87, 558-562.
6. Park, J.; Meisler, A. I.; Cartwright, C. A. c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 1993, 5, 2627-2635.
7. Lutz, M. P.; Esser, I. B.; Flossmann-Kast, B. B.; Vogelmann, R.; Luhrs, H.; Friess, H.; Buchler, M. W.; Adler, G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 1998, 243, 503-508.
8. Majumder, S.; Brown, K.; Qiu, F. H.; Besmer, P. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol. Cell Biol. 1988, 8, 4896-4903.
9. Blume-Jensen, P.; Claesson-Welsh, L.; Siegbahn, A.; Zsebo, K. M.; Westermark, B.; Heldin, C. H. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J. 1991, 10, 4121-4128.
10. Fleischman, R. A. From white spots to stem cells: the role of the Kit receptor in mammalian development. Trends Genet. 1993, 9, 285-290.
11. Russell, E. S. Hereditary anemias of the mouse: a review for geneticists. Adv. Genet. 1979, 20, 357-359.
12. Kitamura, Y.; Go, S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979, 53, 492-497.
13. Huizinga, J. D.; Thuneberg, L.; Kluppel, M.; Malysz, J.; Mikkelsen, H. B.; Bernstein, A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373, 347-349.
14. Isozaki, K.; Hirota, S.; Nakama, A.; Miyagawa, J.; Shinomura, Y.; Xu, Z.; Nomura, S.; Kitamura, Y. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995, 109, 456-464.
15. Linnekin, D. Early signalling pathways activated by c-Kit in hematopoietic cells. Int. J. Biochem. Cell Biol. 1999, 31, 1053-1074.
16. Taylor, M. L.; Metcalfe, D. D. Kit signal transduction. Hematol. Oncol. Clin. North Am. 2000, 14, 517-535.
17. Piao, X.; Paulson, R.; van der Geer, P.; Pawson, T.; Bernstein, A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA 1996, 93, 14665-14669.
18. Chian, R.; Young, S.; Danilkovitch-Miagkova, A.; Ronnstrand, L.; Leonard, E.; Ferrao, P.; Ashman, L.; Linnekin, D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001, 98, 1365-1373.
19. Savage, D. G.; Antman, K. H. lmatinib mesylate - a new oral targeted therapy. N. Engl. J. Med. 2002, 346, 683-693.
20. Borg, C.; Terme, M.; Taieb, J.; Menard, C.; Flament, C.; Robert, C.; Maruyama, K.; Wakasugi, H.; Angevin, E.; Thielemans, K.; Le Cesne, A.; Chung-Scott, V.; Lazar, V.; Tchou, I.; Crepineau, F.; Lemoine, F.; Bernard, J.; Fletcher, J. A.; Turhan, A.; Blay, J. Y.; Spatz, A.; Emile, J. F.; Heinrich, M. C.; Mecheri, S.; Tursz, T.; Zitvogel, L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 2004, 114, 379-388.
21. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347, 472-480.
22. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
23. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001, 344, 1038-1042.
24. van Oosterom, A. T.; Judson, I.; Verweij, J.; Stroobants, S.; Donato di Paola, E.; Dimitrijevic, S.; Martens, M.; Webb, A.; Sciot, R.; Van Glabbeke, M.; Silberman, S.; Nielsen, O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet 2001, 358, 1421-1423.
25. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, M.; Kurata, A.; Takeda, M.; Muhammad Tunio, G.; Matsuzawa, Y.; Kanakura, Y.; Shinomura, Y.; Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279, 577-580.
26. Heinrich, M. C.; Corless, C. L.; Demetri, G. D.; Blanke, C. D.; von Mehren, M.; Joensuu, H.; McGreevey, L. S.; Chen, C. J.; Van den Abbeele, A. D.; Druker, B. J.; Kiese, B.; Eisenberg, B.; Roberts, P. J.; Singer, S.; Fletcher, C. D.; Silberman, S.; Dimitrijevic, S.; Fletcher, J. A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003, 21, 4342-4349.
27. Heinrich, M. C.; Corless, C. L.; Duensing, A.; McGreevey, L.; Chen, C. J.; Joseph, N.; Singer, S.; Griffith, D. J.; Haley, A.; Town, A.; Demetri, G. D.; Fletcher, C. D.; Fletcher, J. A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299, 708-710.
28. Verweij, J.; Casali, P. G.; Zalcberg, J.; LeCesne, A.; Reichardt, P.; Blay, J. Y.; Issels, R.; van Oosterom, A.; Hogendoorn, P. C.; Van Glabbeke, M.; Bertulli, R.; Judson, I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364, 1127-1134.
29. Ebert, M.; Nitsche, B.; Roecken, C.; Hosius, C.; Gschaidmeier, H.; Kahl, S.; Malfertheiner, P. Therapie des fortgeschrittenen Pankreaskarzinoms mit dem Tyrosinkinasen-Inhibitor livec: Ergebnisse einer prospektiv, randomisierten klinischen Studie. Z. Gastroenterol. 2004, 42, 887A.
30. Chen, L. L.; Trent, J. C.; Wu, E. F.; Fuller, G. N.; Ramdas, L.; Zhang, W.; Raymond, A. K.; Prieto, V. G.; Oyedeji, C. O.; Hunt, K. K.; Pollock, R. E.; Feig, B. W.; Hayes, K. J.; Choi, H.; Macapinlac, H. A.; Hittelman, W.; Velasco, M. A.; Patel, S.; Burgess, M. A.; Benjamin, R. S.; Frazier, M. L. A missense mutation in KIT kinase domain I correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004, 64, 5913-5919.
31. Debiec-Rychter, M.; Cools, J.; Dumez, H.; Sciot, R.; Stul, M.; Mentens, N.; Vranckx, H.; Wasag, B.; Prenen, H.; Roesel, J.; Hagemeijer, A.; Van Oosterom, A.; Marynen, P. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128, 270-279.
32. Ullrich, A.; Coussens, L.; Hayflick, J. S.; Dull, T. J.; Gray, A.; Tam, A. W.; Lee, J.; Yarden, Y.; Libermann, T. A.; Schlessinger, J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
33. Raymond, E.; Faivre, S.; Armand, J. P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60(Suppl 1), 15-23; discussion 41-42.
34. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
35. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
36. Kuan, C. T.; Wikstrand, C. J.; Bigner, D. D. EOF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 2001, 8, 83-96.
37. Hackel, P. O.; Zwick, E.; Prenzel, N.; Ullrich, A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 1999, 11, 184-189.
38. Rak, J.; Yu, J. L.; Klement, G.; Kerbel, R. S. Oncogenes and angiogenesis: signalling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 2000, 5, 24-33.
39. Ranson, M.; Hammond, L. A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P. I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E. K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. 2002, 20, 2240-2250.
40. Herbst, R. S.; Maddox, A. M.; Rothenberg, M. L.; Small, E. J.; Rubin, E. H.; Baselga, J.; Rojo, F.; Hong, W. K.; Swaisland, H.; Averbuch, S. D.; Ochs, J.; LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J. Clin. Oncol. 2002, 20, 3815-3825.
41. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
42. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J. Sr.; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
43. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
44. Xiong, H. Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R. A.; Deutsch, J.; Needle, M.; Abbruzzese, J. L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol. 2004, 22, 2610-2616.
45. Liekens, S.; De Clercq, E.; Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001, 61, 253-270.
46. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
47. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. C.; Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266, 11947-11954.
48. Masood, R.; Cai, J.; Zheng, T.; Smith, D. L.; Naidu, Y.; Gill, P. S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. USA 1997, 94, 979-984.
49. Ortega, N.; Jonca, F.; Vincent, S.; Favard, C.; Ruchoux, M. M.; Plouet, J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am. J. Pathol. 1997, 151, 1215-1224.
50. Gerber, H. P.; Vu, T. H.; Ryan, A. M.; Kowalski, J.; Werb, Z.; Ferrara, N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 1999, 5, 623-628.
51. Nor, J. E.; Christensen, J.; Mooney, D. J.; Polverini, P. J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 1999, 154, 375-384.
52. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
53. Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 60-65.
54. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T. Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S. Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R. Kabbinavar, F. N. Engl. J. Med. 2004, 350, 2335-2342.
55. Willett, C. G.; Boucher, Y.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Tong, R. T.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Kozin S. V.; Mino, M.; K.S., C.; Scadden, D. T.; Hartford, A. C. Fischman, A. J.; Clark, J. W.; Ryan, D. P.; Zhu, A. X. Blaszkowsky, L. S.; Chen, H. X.; Shellito, P. C.; Lauwers, G. Y. Jain, R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
56. Hsu, C.; Chen, C. N.; Chen, L. T.; Wu, C. Y.; Yang, P. M.; Lai, M. Y.; Lee, P. H.; Cheng, A. L. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003, 65, 242-249.
57. End, D. W.; Smets, G.; Todd, A. V.; Applegate, T. L.; Fuery, C. J.; Angibaud, P.; Venet, M.; Sanz, G.; Poignet, H.; Skrzat, S.; Devine, A.; Wouters, W.; Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001, 61, 131-137.
58. Grunewald, K.; Lyons, J.; Frohlich, A.; Feichtinger, H.; Weger, R. A.; Schwab, G.; Janssen, J. W.; Bartram, C. R. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer 1989, 43, 1037-1041.
59. Sebti, S. M.; Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase 1 inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert. Opin. Investig. Drugs 2000, 9, 2767-2782.
60. Cohen, S. J.; Ho, L.; Ranganathan, S.; Abbruzzese, J. L.; Alpaugh, R. K.; Beard, M.; Lewis, N. L.; McLaughlin, S.; Rogatko, A.; Perez-Ruixo, J. J.; Thistle, A. M.; Verhaeghe, T.; Wang, H.; Weiner, L. M.; Wright, J. J.; Hudes, G. R.; Meropol, N. J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21, 1301-1306.
61. Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W. L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; Safran, H.; Humblet, Y.; Ferez Ruixo, J.; Ma, Y.; Von Hoff, D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004,22, 1430-1438.
62. Forrester, K.; Almoguera, C.; Han, K.; Grizzle, W. E.; Perucho, M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327, 298-303.
63. Rao, S.; Cunningham, D.; de Gramont, A.; Scheithauer, W.; Smakal, M.; Humblet, Y.; Kourteva, G.; Iveson, T.; Andre, T.; Dostalova, J.; Illes, A.; Belly, R.; Perez-Ruixo, J. J.; Park, Y. C.; Palmer, P. A. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 2004, 22, 3950-3957.
64. Ramnath, N.; Creaven, P. J. Matrix metalloproteinase inhibitors. Curr. Oncol. Rep. 2004, 6, 96-102.
65. Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 2002, 86, 1864-1870.
66. Bramhall, S. R.; Schulz, J.; Nemunaitis, J.; Brown, P. D.; Baillet, M.; Buckels, J. A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87, 161-167.
67. Moore, M. J.; Hamm, J.; Dancey, J.; Eisenberg, P. D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B.; Tu, D.; Ottaway, J.; Humphrey, R.; Seymour, L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21, 3296-3302.
68. Mitchell, B. S. The proteasome-an emerging therapeutic target in cancer. N. Engl. J. Med. 2003, 348, 2597-2598.
69. Teicher, B. A.; Ara, G.; Herbst, R.; Palombella, V. J.; Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 1999, 5, 2638-2645.
70. Barbet, N. C.; Schneider, U.; Helliwell, S. B.; Stansfield, I.; Tuite, M. F.; Hall, M. N. TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell 1996, 7, 25-42.
71. Maki, R. G. Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. Curr. Treat. Options Gastroenterol. 2004, 7, 13-17.
72. Kneteman, N. M.; Oberholzer, J.; Al Saghier, M.; Meeberg, G. A.; Blitz, M.; Ma, M. M.; Wong, W. W.; Gutfreund, K.; Mason, A. L.; Jewell, L. D.; Shapiro, A. M.; Bain, V. G.; Bigam, D. L. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004, 10, 1301-1311.
73. Garcia Rodriguez, L. A.; Huerta-Alvarez, C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000, 11, 376-381.
74. Thun, M. J.; Namboodiri, M. M.; Heath, C. W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325, 1593-1596.
75. Giovannucci, E.; Egan, K. M.; Hunter, D. J.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995, 333, 609-614.
76. Sjodahl, R. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am. J. Med. 2001, 110, 66S-69S.
77. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
78. Pietras, K.; Ostman, A.; Sjoquist, M.; Buchdunger, E.; Reed, R. K.; Heldin, C. H.; Rubin, K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001, 61, 2929-2934.
79. Pietras, K.; Rubin, K.; Sjoblom, T.; Buchdunger, E.; Sjoquist, M.; Heldin, C. H.; Ostman, A. Inhibition of PDGF receptor signalling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62, 5476-5484.
80. Duensing, A.; Medeiros, F.; McConarty, B.; Joseph, N. E.; Panigrahy, D.; Singer, S.; Fletcher, C. D.; Demetri, G. D.; Fletcher, J. A. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23, 3999-4006.
81. Zonder, J. A.; Shields, A. F.; Zalupski, M.; Chaplen, R.; Heilbrun, L. K.; Arlauskas, P.; Philip, P. A. A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 2001, 7, 38-42.
82. Senderowicz, A. M. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003, 22, 6609-6620.
83. Rinehart, J.; Adjei, A. A.; Lorusso, P. M.; Waterhouse, D.; Hecht, J. R.; Natale, R. B.; Hamid, O.; Varterasian, M.; Asbury, P.; Kaldjian, E. P.; Gulyas, S.; Mitchell, D. Y.; Herrera, R.; Sebolt-Leopold, J. S.; Meyer, M. B. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22, 4456-4462
84. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305, 399-401.
85. Piekarz, R.; Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 2004, 10, 2289-2298.
86. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. K; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan, K. K.; Goldspiel, B.; Fojo, A. T.; Balcerzak, S. P.; Bates, S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002, 8, 718-728.
87. Kung, A. L.; Zabludoff, S. D.; France, D. S.; Freedman, S. J.; Tanner, E. A.; Vieira, A.; Cornell-Kennon, S.; Lee, J.; Wang, B.; Wang, J.; Memmert, K.; Naegeli, H. U.; Petersen, F.; Eck, M. J.; Bair, K. W,; Wood, A. W.; Livingston, D. M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6, 33-43.
88. Zhou, H.; Kuang, J.; Zhong, L.; Kuo, W. L.; Gray, J. W.; Sahin, A.; Brinkley, B. R.; Sen, S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20, 189-193.
89. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17, 3052-3065.
90. Sausville, E. A. Aurora kinases dawn as cancer drug targets. Nat. Med. 2004, 10, 234-235.
91. Thayer, S. P.; di Magliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856.
92. Muraoka, R. S.; Dumont, N.; Ritter, C. A.; Dugger, T. C.; Brantley, D. M.; Chen, J.; Easterly, E.; Roebuck, L. R.; Ryan, S.; Gotwals, P. J.; Koteliansky, V.; Arteaga, C. L. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002, 109, 1551-1559.
93. Yang, Y. A.; Dukhanina, O.; Tang, B.; Mamura, M.; Letterio, J. J.; MacGregor, J.; Patel, S. C.; Khozin, S.; Liu, Z. Y.; Green, J.; Anver, M. R.; Merlino, G.; Wakefield, L. M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 2002, 109, 1607-1615.
94. Bandyopadhyay, A.; Lopez-Casillas, F.; Malik, S. N.; Montiel, J. L.; Mendoza, V.; Yang, J.; Sun, L. Z. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 2002, 62, 4690-4695.
95. Fakhrai, H.; Dorigo, O.; Shawler, D. L.; Lin, H.; Mercola, D.; Black, K. L.; Royston, I.; Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA 1996, 93, 2909-2914.
96. Sawyer, J. S.; Beight, D. W.; Britt, K. S.; Anderson, B. D.; Campbell, R. M.; Goodson, T. Jr.; Herron, D. K.; Li, H. Y.; McMillen, W. T.; Mort, N.; Parsons, S.; Smith, E. C.; Wagner, J. R.; Yan, L.; Zhang, F.; Yingling, J. M. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg. Med. Chem. Lett. 2004, 14, 3581-3584.
97. DaCosta Byfield, S.; Major, C.; Laping, N. J.; Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2004, 65, 744-752.
98. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64, 4931-4941.
99. Strumberg, D.; Richly, H.; Hilger, R. A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C. G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M. E.; Seeber, S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005, 23, 965-972.
100. Sun, L.; Liang, C; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J. Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116-1119.
101. Bates, D. ZD-6474. AstraZeneca. Curr. Opin. Investig. Drugs 2003, 4, 1468-1472.
102. Raben, D.; Bianco, C.; Damiano, V.; Bianco, R.; Melisi, D.; Mignogna, C.; D'Armiento, F. P.; Cionini, L.; Bianco, A. R.; Tortora, G.; Ciardiello, F.; Bunn, P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZDl839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol. Cancer Ther. 2004, 3, 977-983.